Publication Name	World Journal of Hepatology
Manuscript ID	16781
Country	Türkiye

Received	2015-01-29 08:39
Peer-Review Started	2015-02-02 09:01
To Make the First Decision	2015-04-10 17:50
Return for Revision	2015-04-16 13:24
Revised	2015-05-06 01:37
Second Decision	2015-06-12 16:30
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-06-19 17:52
Articles in Press	2015-06-19 17:52
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-25 13:51
Publish the Manuscript Online	2015-07-10 17:51

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Bulent Baran
Funding Agency and Grant Number
Corresponding Author	Bulent Baran, MD, FEBG, Department of Gastroenterology, Koç University Hospital, Davutpasa St., Zeytinburnu, 34010 Istanbul, Turkey. drbulentbaran@gmail.com
Key Words	Hepatitis B virus; Hepatocellular carcinoma; Prevention; Nucleos(t)ide analogues; Risk factors
Core Tip	After the introduction of potent nucleos(t)ide analogues with high genetic barrier to resistance, main-taining long-term virological suppression is achievable in almost all patients with chronic hepatitis B. The currently recommended first-line antiviral drugs, entecavir and tenofovir, can significantly reduce hepatocellular carci-noma (HCC) incidence, but the observed risk under efficient therapy is not zero in the long-term. There are established risk factors including age, gender, family history, low platelet levels, presence of cirrhosis or severity of liver disease, which should be incorporated into the clinical decision making to differentiate those patients under risk of developing HCC.
Publish Date	2015-07-10 17:51
Citation	Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1742-1754
URL	http://www.wjgnet.com/1948-5182/full/v7/i13/1742.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i13.1742

Full Article (PDF)	WJH-7-1742.pdf
Full Article (Word)	WJH-7-1742.doc
Manuscript File	16781-Review.docx
Answering Reviewers	16781-Answering reviewers.pdf
Audio Core Tip	16781-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	16781-Conflict-of-interest statement.pdf
Copyright License Agreement	16781-Copyright assignment.pdf
Peer-review Report	16781-Peer-review(s).pdf
Scientific Misconduct Check	16781-Scientific misconduct check.pdf
Scientific Editor Work List	16781-Scientific editor work list.pdf